Iris Lin
Why did you decide to pursue a graduate degree?
The completion of my undergraduate studies coincided with several major breakthroughs in the field of cancer immunology. Seeing research leading to exciting and tangible advances in medicine and technology and generating impact at the patient level inspired me to begin my journey as a clinician-scientist.
Why did you decide to study at UBC?
UBC has been consistently ranked in the top five percent of universities in the world, renowned for excellence in research, teaching, and creating global impact. As a hub for experts and leading scientists in many fields, this vibrant community is a great environment in which to learn, engage, explore, and grow.
What is it specifically, that your program offers, that attracted you?
My program is unique in that it provides opportunities to develop not only as a scientist but also as a clinician. I think that this dual perspective allows for greater insight into the clinical risk factors and biology underpinning the development and progression of the disease and drives home the ultimate end goal of my research – improving patient lives.
What was the best surprise about UBC or life in Vancouver?
The strong support network within my program and faculty, and the wonderful people I’ve met over the course of my studies!
What aspects of your life or career before now have best prepared you for your UBC graduate program?
In addition to didactic learning, being accountable for my own university experience, exploring diverse opportunities and interests, and taking leaps of faith have prepared me for the ups and downs of graduate school.
What advice do you have for new graduate students?
You are not alone! I learned that being connected and engaged was hugely important to my academic and professional success, as well as for my mental health and overall well-being.
Learn more about Iris's research
Cancer has been historically named, “the wound that does not heal,” given its ability to impair and shape the inflammatory process to promote tumour growth and spread. These pathways have been extensively studied in various cancers, but the role of inflammation in premalignancy has been investigated to a much lesser extent. Oral cancer is often preceded by clinically identifiable premalignant lesions. However, not all these lesions progress; identifying and treating high-risk lesions at an early stage is key in improving patient survival and limiting disease morbidity. Through the investigation of molecular and clinical markers, we aim to elucidate the underlying biology of the inflammatory process in the early stages of malignant transformation and how this translates to risk. The outcome of this study will inform clinical decision-making models to aid in early detection and triage.
